MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
UNC Lineberger Comprehensive Cancer Center
Study ID
NCT04073966
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • Neurocognitive Deficit
  • Radiation Exposure
  • White Matter Alterations

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.

Key Dates

First listed
Aug 29, 2019
Start date
Dec 4, 2019
Status verified
Aug 2026
Primary completion
May 31, 2028
Completion
May 31, 2029

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Radiation-Induced White Matter Injury [ Time Frame: One year after SRS completion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel HillNorth Carolina27599
Olivia Morton
[email protected]
984-974-8441
Colette J Shen, MD, PhD (PRINCIPAL_INVESTIGATOR)
Tong Zhu, PhD, DABR (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chapel Hill, NC

By research site
University of North Carolina at Chapel Hill, Department of Radiation Oncology· Chapel Hill, NC

Related Studies